{
  "id": "42_ref_0",
  "query": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
  "query_data": {
    "id": "42_ref_0",
    "original_id": 42,
    "refined_index": 0,
    "question": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
    "answer": "{'(1)': {'MW': 246.2, 'logP': -0.9, 'TPSA': 92.0, 'HBD': 3, 'HBA': 5, 'RB': 4, 'Lipinski_violations_eval_1': 0, 'Lipinski_violations_eval_2': 0, 'result_relation': '两次结果相同（均满足规则）'}, '(2)': {'optimization_method': 'ETKDG', 'force_field': 'MMFF', 'max_iterations': 500, 'converged': True, 'total_energy': '72.8 kcal/mol', 'Rg': 2.35, 'PMI': [120.4, 230.8, 350.9], 'asphericity': 0.24, 'eccentricity': 0.78}, '(3)': {'SAS_raw': 4.7, 'SAS_final_1dp': 4.7, 'source': '题面给定SAS_raw', 'range_check': '[1,10]内'}, '(4)': {'path_2D': '/images/Floxuridine_2D.png', 'path_3D': '/models/Floxuridine_3D.sdf', 'usage': '2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性'}, '(5)': {'summary_index': {'P1': '(1)中的理化性质与Lipinski评估结果', 'G1': '(2)中的几何优化与形状描述符', 'S1': '(3)中的最终SAS', 'Paths': '(4)中的2D/3D路径'}, 'cross_checks': ['SAS范围：S1∈[1,10]', 'Lipinski两次评估结果相同，均满足规则', '理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征'], 'overall_conclusion': '满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征'}}",
    "metadata": {
      "subject": "化学",
      "topic": "药物化学与合成可及性",
      "image_path": [],
      "solution_steps": [
        "【分子识别与解析】解析5-Fluorodeoxyuridine的SMILES字符串：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O",
        "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法计算合成可及性分数",
        "SAS基于分子复杂度、环系统、立体化学和已知合成片段进行统计评估",
        "获得SAS = 3.5，对应\"相对容易合成\"（2.0-4.0范围）",
        "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整的分子信息",
        "分子式：C9H11FN2O5，分子量：246.07 g/mol",
        "LogP = -1.68（亲水性强），TPSA = 104.55 Å²（极性表面积大）",
        "氢键供体：3，氢键受体：6，可旋转键：2",
        "芳香环：1（嘧啶环），总环数：2（嘧啶环+糖环）",
        "【Lipinski成药性评估】检查Lipinski五规则的违规情况",
        "✓ MW(246.07) ≤ 500，✓ LogP(-1.68) ≤ 5，✓ HBD(3) ≤ 5，✓ HBA(6) ≤ 10",
        "违规数 = 0，类药性 = ✓ 是",
        "【3D可视化】调用 chem_visualizer 生成2D结构图和3D投影图",
        "生成图像：5_Fluorodeoxyuridine_2d.png（平面结构）",
        "5_Fluorodeoxyuridine_3d_projection.png（3D投影）",
        "5_Fluorodeoxyuridine_3d_matplotlib.png（3D立体图）",
        "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
        "初始能量：-0.55 kcal/mol → 优化后能量：-30.79 kcal/mol",
        "能量降低：ΔE = -30.24 kcal/mol（结构显著稳定化）",
        "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
        "主惯性矩：PMI1=496.58, PMI2=2099.67, PMI3=2215.85 amu·Ų",
        "归一化惯性矩比：NPR1=0.224, NPR2=0.948",
        "分子形状：极端棒状/纤维状（NPR1<0.5, NPR2>0.95）",
        "回转半径：Rg = 3.126 Å（分子尺寸的特征长度）",
        "非球形度：asphericity = 0.478（显著偏离球形）",
        "偏心率：eccentricity = 0.975（高度拉伸的椭球形）",
        "【合成难度评估】根据SAS=3.5给出合成难度评价",
        "合成难度：相对容易合成（★★☆☆☆）",
        "核苷类似物的典型复杂度，适合药物开发",
        "【药物应用背景】5-FdU是胸苷酸合成酶抑制剂，用于治疗结直肠癌和肝癌",
        "商品名：Floxuridine, FUDR",
        "作用机制：干扰DNA合成，诱导癌细胞凋亡",
        "【最终答案】合成可及性分数 SAS = 3.5"
      ],
      "tool_expected": [
        "calculate_synthetic_accessibility",
        "mol_basic_physicochemical_info",
        "chem_visualizer",
        "optimize_geometry",
        "get_3d_properties"
      ],
      "golden_answer": [
        {
          "(1)": {
            "MW": 246.2,
            "logP": -0.9,
            "TPSA": 92.0,
            "HBD": 3,
            "HBA": 5,
            "RB": 4,
            "Lipinski_violations_eval_1": 0,
            "Lipinski_violations_eval_2": 0,
            "result_relation": "两次结果相同（均满足规则）"
          },
          "(2)": {
            "optimization_method": "ETKDG",
            "force_field": "MMFF",
            "max_iterations": 500,
            "converged": true,
            "total_energy": "72.8 kcal/mol",
            "Rg": 2.35,
            "PMI": [
              120.4,
              230.8,
              350.9
            ],
            "asphericity": 0.24,
            "eccentricity": 0.78
          },
          "(3)": {
            "SAS_raw": 4.7,
            "SAS_final_1dp": 4.7,
            "source": "题面给定SAS_raw",
            "range_check": "[1,10]内"
          },
          "(4)": {
            "path_2D": "/images/Floxuridine_2D.png",
            "path_3D": "/models/Floxuridine_3D.sdf",
            "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
          },
          "(5)": {
            "summary_index": {
              "P1": "(1)中的理化性质与Lipinski评估结果",
              "G1": "(2)中的几何优化与形状描述符",
              "S1": "(3)中的最终SAS",
              "Paths": "(4)中的2D/3D路径"
            },
            "cross_checks": [
              "SAS范围：S1∈[1,10]",
              "Lipinski两次评估结果相同，均满足规则",
              "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
            ],
            "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
          }
        }
      ],
      "original_question_id": "42",
      "test_type": "refined",
      "dataset_key": "merged_questions_augmented",
      "trace_root": "/root/workspace/hbz/MutliSciTool/tracetoanalyze/traces"
    },
    "usage_tool_protocol": [
      {
        "type": "function",
        "function": {
          "name": "calculate_synthetic_accessibility",
          "description": "计算分子的合成可及性分数（Synthetic Accessibility Score, SAS）。基于Ertl-Schuffenhauer算法，评估有机分子的合成难度。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串，或化学名称（会自动转换）。例如: 'CCO'（乙醇）, 'CC(=O)Oc1ccccc1C(=O)O'（阿司匹林）, 'aspirin'"
              }
            },
            "required": [
              "smiles"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py",
          "return_type": "float",
          "return_range": "1.0-10.0",
          "return_interpretation": "1.0=非常容易合成, 2.0-4.0=相对容易, 4.0-6.0=中等难度, 6.0-8.0=较难, 8.0-10.0=非常难",
          "algorithm": "Ertl & Schuffenhauer (2009) - 基于分子复杂度和片段贡献",
          "reference": "Journal of Cheminformatics, 1(1), 8"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "mol_basic_physicochemical_info",
          "description": "计算分子的基本理化性质和类药性评估。提供分子的基本信息、物化性质和Lipinski五规则评估。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串，或化学名称（会自动转换）。例如: 'CCO', 'CC(=O)Oc1ccccc1C(=O)O', 'aspirin'"
              }
            },
            "required": [
              "smiles"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "chem_visualizer",
          "description": "分子可视化工具，支持批量生成分子的2D结构图和3D结构图。直接生成图片文件到当前目录。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "molecules": {
                "type": "object",
                "description": "分子字典，键为分子名称，值为SMILES字符串。例如: {'ethanol': 'CCO', 'benzene': 'c1ccccc1'}"
              }
            },
            "required": [
              "molecules"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_visualize.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "optimize_geometry",
          "description": "对分子进行3D几何优化，使用力场方法最小化能量。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串"
              },
              "method": {
                "type": "string",
                "description": "3D坐标生成方法",
                "enum": [
                  "ETKDGv3",
                  "ETKDG",
                  "KDG",
                  "distance_geometry"
                ]
              },
              "force_field": {
                "type": "string",
                "description": "力场类型，MMFF（Merck分子力场）或UFF（通用力场）",
                "enum": [
                  "MMFF",
                  "UFF"
                ]
              },
              "max_iters": {
                "type": "integer",
                "description": "最大优化迭代次数，默认200"
              }
            },
            "required": [
              "smiles",
              "method"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py"
        }
      },
      {
        "type": "function",
        "function": {
          "name": "get_3d_properties",
          "description": "计算分子的3D性质，包括主惯性矩、形状描述符、回转半径等。",
          "strict": true,
          "parameters": {
            "type": "object",
            "properties": {
              "smiles": {
                "type": "string",
                "description": "分子的SMILES表示字符串"
              },
              "method": {
                "type": "string",
                "description": "3D坐标生成方法",
                "enum": [
                  "ETKDGv3",
                  "ETKDG",
                  "KDG"
                ]
              },
              "conf_id": {
                "type": "integer",
                "description": "构象ID，默认为0（第一个构象）"
              }
            },
            "required": [
              "smiles",
              "method"
            ],
            "additionalProperties": false
          }
        },
        "additionalProperties": {
          "function_path": "./tools/chemistry_tools/molecule_analyzer.py"
        }
      }
    ],
    "refined_version_data": {
      "refined_question": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
      "final_answer": {
        "(1)": {
          "MW": 246.2,
          "logP": -0.9,
          "TPSA": 92.0,
          "HBD": 3,
          "HBA": 5,
          "RB": 4,
          "Lipinski_violations_eval_1": 0,
          "Lipinski_violations_eval_2": 0,
          "result_relation": "两次结果相同（均满足规则）"
        },
        "(2)": {
          "optimization_method": "ETKDG",
          "force_field": "MMFF",
          "max_iterations": 500,
          "converged": true,
          "total_energy": "72.8 kcal/mol",
          "Rg": 2.35,
          "PMI": [
            120.4,
            230.8,
            350.9
          ],
          "asphericity": 0.24,
          "eccentricity": 0.78
        },
        "(3)": {
          "SAS_raw": 4.7,
          "SAS_final_1dp": 4.7,
          "source": "题面给定SAS_raw",
          "range_check": "[1,10]内"
        },
        "(4)": {
          "path_2D": "/images/Floxuridine_2D.png",
          "path_3D": "/models/Floxuridine_3D.sdf",
          "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
        },
        "(5)": {
          "summary_index": {
            "P1": "(1)中的理化性质与Lipinski评估结果",
            "G1": "(2)中的几何优化与形状描述符",
            "S1": "(3)中的最终SAS",
            "Paths": "(4)中的2D/3D路径"
          },
          "cross_checks": [
            "SAS范围：S1∈[1,10]",
            "Lipinski两次评估结果相同，均满足规则",
            "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
          ],
          "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
        }
      }
    },
    "metadata_summary": {
      "subject": "化学",
      "topic": "药物化学与合成可及性",
      "test_type": "refined",
      "original_question_id": "42",
      "subject_topic_key": "化学::药物化学与合成可及性"
    }
  },
  "model": "gemini-2.5-pro-thinking-2048",
  "use_tools": true,
  "mode": "tool_mode",
  "rounds": 3,
  "messages": [
    {
      "role": "system",
      "content": "你是一个顶尖的 AI 科学助手，你的任务是解决来自物理、化学、生物等领域的复杂、多模态、多步骤问题。\n\n# 任务指令：两阶段方法\n\n你必须严格遵循以下两个阶段来回答问题：\n\n**阶段 1: 规划 (Planning)**\n在开始执行任何操作之前，你必须首先生成一个高阶的、分步骤的“计划”。这个计划应该概述你打算如何分解问题、使用哪些工具、以及工具之间的依赖关系。\n\n**阶段 2: 执行 (Execution)**\n在提交计划后，你将开始逐一执行。你必须严格遵循以下的 \"ReAct\" 格式 (Thought, Action, Observation)，直到你得出最终答案。\n\n---\n\n**输出格式规范**\n\n**[阶段 1: 规划]**\nPlan:\n\n1. [你的计划步骤 1，例如：分析输入图像中的分子结构]\n2. [你的计划步骤 2，例如：使用 `analyze_molecule` 工具获取 SMILES]\n3. [你的计划步骤 3，例如：将 SMILES 传入 `calculate_properties` 工具]\n4. ...\n5. [你的计划步骤 N，例如：总结所有属性并回答问题]\n\n**[阶段 2: 执行]**\nThought: [描述你当前的思考，你正处于计划的第几步，以及你为什么需要调用这个特定的工具。]\nAction: 请你在这一步发出工具调用\n\n[在你提交 Action 后，你将收到一个 Observation]\n\nObservation: [这里将由评测系统插入工具的返回结果]\n\n[然后你重复这个循环]\n\nThought: [基于上一步的 Observation，你的新思考。]\nAction: 请你在这一步发出工具调用\n\n...\n[当你收集到所有信息并准备好回答时]\n\nThought: [我已收集到所有必要信息，现在可以生成最终答案了。]\nFinal Answer: [这里是对原始问题的最终、完整回答。]"
    },
    {
      "role": "user",
      "content": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。"
    },
    {
      "role": "assistant",
      "content": "[阶段 1: 规划]\nPlan:\n\n1.  使用 `mol_basic_physicochemical_info` 工具，传入 Floxuridine 的 SMILES 字符串，以获取其理化性质和第一次 Lipinski 五规则评估。\n2.  使用 `calculate_synthetic_accessibility` 工具，传入 Floxuridine 的 SMILES 字符串，以获取其合成可及性分数（SAS）作为交叉验证。\n3.  整理并分析所有信息（包括用户输入和工具返回的结果），执行第二次独立的 Lipinski 五规则评估（基于用户提供的数据）。\n4.  比较两次 Lipinski 评估的结果。\n5.  将用户给定的 `SAS_raw` (4.7) 四舍五入到一位小数，并与工具计算的 SAS 分数进行比较。\n6.  根据用户的要求，结构化地汇总所有信息，包括理化性质、3D 几何参数、3D 形状描述符、SAS 分数和可视化路径。\n7.  创建一个交叉校验清单，包括 SAS 范围检查、理化属性评估结果的比较，以及对分子形状和理化属性合理性的说明。\n8.  基于所有分析，给出最终的成药性结论和 SAS 分数。\n\n[阶段 2: 执行]\nThought: 我将首先执行计划的第1步，使用 `mol_basic_physicochemical_info` 工具来计算 Floxuridine 的理化性质和进行第一次 Lipinski 五规则评估。这将为我提供一个基准，以便与用户提供的数据进行比较。\nAction:",
      "tool_calls": [
        {
          "id": "call_a8a1cfd627c7458e844edd5a0ce0b8fc",
          "type": "function",
          "function": {
            "name": "mol_basic_physicochemical_info",
            "arguments": "{\"smiles\":\"OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O\"}"
          }
        }
      ]
    },
    {
      "role": "tool",
      "content": [
        "<tools.chemistry_tools.molecule_analyzer.MoleculeAnalyzer object at 0x7fcd5a283dd0>",
        "\n【基本信息】  SMILES                    OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O  Molecular Formula         C9H11FN2O5  Molecular Weight          246.07  Heavy Atom Count          17  Total Atom Count          17\n【物化性质】  LogP                      -1.68  TPSA                      104.55  H-Bond Donors             3  H-Bond Acceptors          6  Rotatable Bonds           2  Aromatic Rings            1  Total Rings               2\n【Lipinski规则】  违规数: 0  类药性: ✓ 是    ✓ MW ≤ 500    ✓ LogP ≤ 5    ✓ HBD ≤ 5    ✓ HBA ≤ 10"
      ],
      "tool_call_id": "call_a8a1cfd627c7458e844edd5a0ce0b8fc"
    },
    {
      "role": "assistant",
      "content": "我将使用工具来解决这个问题。",
      "tool_calls": [
        {
          "id": "call_36bea7f2c08c45e7816b0b25902b59b0",
          "type": "function",
          "function": {
            "name": "calculate_synthetic_accessibility",
            "arguments": "{\"smiles\":\"OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O\"}"
          }
        }
      ]
    },
    {
      "role": "tool",
      "content": 3.5,
      "tool_call_id": "call_36bea7f2c08c45e7816b0b25902b59b0"
    },
    {
      "role": "assistant",
      "content": "Thought: 我已经收到了 `mol_basic_physicochemical_info` 和 `calculate_synthetic_accessibility` 工具的返回结果。\n\n现在，我将整理所有信息，并按照计划的剩余步骤进行分析和回答。\n\n1.  **理化性质和 Lipinski 评估**:\n    *   用户给定: MW=246.2, logP=-0.9, TPSA=92.0, HBD=3, HBA=5, RB=4\n    *   工具计算: MW=246.07, logP=-1.68, TPSA=104.55, HBD=3, HBA=6, RB=2\n    *   第一次评估 (工具): 0 违例\n    *   第二次评估 (用户给定数据):\n        *   MW = 246.2 (≤ 500) -> Pass\n        *   logP = -0.9 (≤ 5) -> Pass\n        *   HBD = 3 (≤ 5) -> Pass\n        *   HBA = 5 (≤ 10) -> Pass\n        *   结果: 0 违例。\n    *   两次评估结果相同。\n\n2.  **3D 几何优化和形状描述符**:\n    *   用户给定:\n        *   优化: 方法=ETKDG, 力场=MMFF, 最大迭代=500, 收敛=true, 总能量=72.8 kcal/mol\n        *   形状: Rg=2.35, PMI=[120.4, 230.8, 350.9], asphericity=0.24, eccentricity=0.78\n\n3.  **合成可及性分数 (SAS)**:\n    *   用户给定 `SAS_raw` = 4.7\n    *   四舍五入后: SAS = 4.7\n    *   SAS 范围检查: 1 ≤ 4.7 ≤ 10 -> Pass\n    *   工具计算 SAS = 3.5\n\n4.  **可视化路径**:\n    *   用户给定: 2D=\"/images/Floxuridine_2D.png\", 3D=\"/models/Floxuridine_3D.sdf\"\n    *   用途: 核对嘧啶5位氟取代与糖环手性（相对构型）。\n\n5.  **汇总与交叉校验**:\n    *   **数值汇总**: 将所有上述信息整理成表格。\n    *   **交叉校验清单**:\n        *   SAS范围检查: 已完成 (Pass)。\n        *   理化属性重复评估结果: 相同 (均为 0 违例)。\n        *   形状与理化属性的合理性:\n            *   Floxuridine 是一个相对刚性的分子（糖环和嘧啶环），`RB=2`（工具计算）比 `RB=4`（用户给定）更合理。`OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O` 中，可旋转键为 C-C (exocyclic) 和 C-N 键。\n            *   非球形（asphericity=0.24）和高偏心率（eccentricity=0.78）与分子的扁平环状结构和侧链一致。\n            *   高 TPSA (92.0 或 104.55) 和低 logP (-0.9 或 -1.68) 表明分子具有良好的水溶性，这与多个羟基和羰基官能团的存在一致。\n\n6.  **最终结论**:\n    *   成药性: Floxuridine 具有良好的类药性（Lipinski 规则通过）。\n    *   最终 SAS: 4.7 (根据用户要求)。\n\n现在，我将根据这些分析生成最终答案。\nFinal Answer: \n(1) **理化性质与Lipinski五规则评估**\n\n*   **理化性质报告**:\n    *   分子量 (MW): 246.2\n    *   脂水分配系数 (logP): -0.9\n    *   拓扑极性表面积 (TPSA): 92.0 Å²\n    *   氢键供体数 (HBD): 3\n    *   氢键受体数 (HBA): 5\n    *   可旋转键数 (RB): 4\n*   **Lipinski五规则评估**:\n    *   **第一次评估 (基于工具计算值)**:\n        *   MW = 246.07 (≤ 500)\n        *   logP = -1.68 (≤ 5)\n        *   HBD = 3 (≤ 5)\n        *   HBA = 6 (≤ 10)\n        *   **违例数: 0**\n    *   **第二次评估 (基于题面给定值)**:\n        *   MW = 246.2 (≤ 500)\n        *   logP = -0.9 (≤ 5)\n        *   HBD = 3 (≤ 5)\n        *   HBA = 5 (≤ 10)\n        *   **违例数: 0**\n    *   **结果对比**: 两次独立评估的Lipinski五规则违例数**相同**。\n\n(2) **3D几何优化与形状描述符**\n\n*   **3D几何优化参数**:\n    *   方法: ETKDG\n    *   力场: MMFF\n    *   最大迭代次数: 500\n    *   收敛状态: true\n    *   总能量: 72.8 kcal/mol\n*   **3D形状描述符**:\n    *   回转半径 (Rg): 2.35 Å\n    *   主惯性矩 (PMI): [120.4, 230.8, 350.9] amu·Å²\n    *   非球形度 (Asphericity): 0.24\n    *   偏心率 (Eccentricity): 0.78\n\n(3) **合成可及性分数 (SAS)**\n\n*   **最终SAS分数**: 4.7\n*   **来源说明**: 该分数由题面给定的SAS_raw (4.7) 经过四舍五入（保留一位小数）得到。经检查，该值落在[1, 10]的合理范围内。\n\n(4) **2D/3D结构图路径**\n\n*   **2D结构图路径**: \"/images/Floxuridine_2D.png\"\n*   **3D结构图路径**: \"/models/Floxuridine_3D.sdf\"\n*   **用途说明**: 这些结构图用于直观核对Floxuridine分子的关键结构特征，特别是嘧啶环5号位的氟原子取代以及脱氧核糖环上的手性中心（相对构型）。\n\n(5) **数值汇总、交叉校验与结论**\n\n*   **数值汇总**:\n| 参数 | 题面给定值 | 工具计算值 | 单位 |\n| :--- | :--- | :--- | :--- |\n| MW | 246.2 | 246.07 | amu |\n| logP | -0.9 | -1.68 | - |\n| TPSA | 92.0 | 104.55 | Å² |\n| HBD | 3 | 3 | - |\n| HBA | 5 | 6 | - |\n| RB | 4 | 2 | - |\n| Lipinski违例 | 0 | 0 | - |\n| SAS | 4.7 | 3.5 | - |\n\n*   **交叉校验清单**:\n    *   **SAS范围检查**: 最终SAS分数4.7位于[1, 10]区间内，检查通过。\n    *   **理化属性评估**: 基于题面给定值和工具计算值的两次Lipinski规则评估结果**相同**，均为0个违例。\n    *   **形状与理化属性合理性**: 分子具有较高的极性（TPSA > 90）和亲水性（logP < 0），这与分子结构中含有多个羟基、羰基和氮原子相符。非球形度（0.24）和偏心率（0.78）也合理地反映了其非对称、扁平的环状结构。工具计算的可旋转键数（2）比题面给定的（4）更符合标准定义。\n\n*   **总体结论**:\n    *   **成药性**: Floxuridine（5-氟脱氧尿苷）完全符合Lipinski五规则，表现出**良好**的类药性。\n    *   **最终SAS**: **4.7**"
    },
    {
      "role": "user",
      "content": "现在请仅输出严格 JSON，必须完全匹配以下结构（键名、层级、字段齐全），所有数值用数字表示（保留2-3位小数），布尔用 true/false，字符串填写说明文字。不要输出任何解释文字或前后缀，也不要多余字段；若无法计算某值请给出可解析的近似值。\n\n{\n  \"(1)\": {\n    \"MW\": \"[数值]\",\n    \"logP\": \"[数值]\",\n    \"TPSA\": \"[数值]\",\n    \"HBD\": \"[数值]\",\n    \"HBA\": \"[数值]\",\n    \"RB\": \"[数值]\",\n    \"Lipinski_violations_eval_1\": \"[数值]\",\n    \"Lipinski_violations_eval_2\": \"[数值]\",\n    \"result_relation\": \"[字符串]\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"[字符串]\",\n    \"force_field\": \"[字符串]\",\n    \"max_iterations\": \"[数值]\",\n    \"converged\": \"[布尔值]\",\n    \"total_energy\": \"[字符串]\",\n    \"Rg\": \"[数值]\",\n    \"PMI\": \"[3个数值的数组]\",\n    \"asphericity\": \"[数值]\",\n    \"eccentricity\": \"[数值]\"\n  },\n  \"(3)\": {\n    \"SAS_raw\": \"[数值]\",\n    \"SAS_final_1dp\": \"[数值]\",\n    \"source\": \"[字符串]\",\n    \"range_check\": \"[字符串]\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"[字符串]\",\n    \"path_3D\": \"[字符串]\",\n    \"usage\": \"[字符串]\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"[字符串]\",\n      \"G1\": \"[字符串]\",\n      \"S1\": \"[字符串]\",\n      \"Paths\": \"[字符串]\"\n    },\n    \"cross_checks\": \"[3个字符串的数组]\",\n    \"overall_conclusion\": \"[字符串]\"\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "```json\n{\n  \"(1)\": {\n    \"MW\": 246.20,\n    \"logP\": -0.90,\n    \"TPSA\": 92.00,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"两次评估结果相同\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [\n      120.40,\n      230.80,\n      350.90\n    ],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"题面给定\",\n    \"range_check\": \"通过，值在[1,10]范围内\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化性质与Lipinski规则\",\n      \"G1\": \"3D几何与形状描述符\",\n      \"S1\": \"合成可及性分数\",\n      \"Paths\": \"2D/3D结构图路径\"\n    },\n    \"cross_checks\": [\n      \"SAS范围检查: 通过\",\n      \"理化属性重复评估结果: 相同\",\n      \"形状与理化属性合理性: 合理\"\n    ],\n    \"overall_conclusion\": \"Floxuridine表现出良好的类药性 (Lipinski 0违例)，最终SAS为4.7\"\n  }\n}\n```"
    }
  ],
  "metadata": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "image_path": [],
    "solution_steps": [
      "【分子识别与解析】解析5-Fluorodeoxyuridine的SMILES字符串：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O",
      "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法计算合成可及性分数",
      "SAS基于分子复杂度、环系统、立体化学和已知合成片段进行统计评估",
      "获得SAS = 3.5，对应\"相对容易合成\"（2.0-4.0范围）",
      "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整的分子信息",
      "分子式：C9H11FN2O5，分子量：246.07 g/mol",
      "LogP = -1.68（亲水性强），TPSA = 104.55 Å²（极性表面积大）",
      "氢键供体：3，氢键受体：6，可旋转键：2",
      "芳香环：1（嘧啶环），总环数：2（嘧啶环+糖环）",
      "【Lipinski成药性评估】检查Lipinski五规则的违规情况",
      "✓ MW(246.07) ≤ 500，✓ LogP(-1.68) ≤ 5，✓ HBD(3) ≤ 5，✓ HBA(6) ≤ 10",
      "违规数 = 0，类药性 = ✓ 是",
      "【3D可视化】调用 chem_visualizer 生成2D结构图和3D投影图",
      "生成图像：5_Fluorodeoxyuridine_2d.png（平面结构）",
      "5_Fluorodeoxyuridine_3d_projection.png（3D投影）",
      "5_Fluorodeoxyuridine_3d_matplotlib.png（3D立体图）",
      "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
      "初始能量：-0.55 kcal/mol → 优化后能量：-30.79 kcal/mol",
      "能量降低：ΔE = -30.24 kcal/mol（结构显著稳定化）",
      "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
      "主惯性矩：PMI1=496.58, PMI2=2099.67, PMI3=2215.85 amu·Ų",
      "归一化惯性矩比：NPR1=0.224, NPR2=0.948",
      "分子形状：极端棒状/纤维状（NPR1<0.5, NPR2>0.95）",
      "回转半径：Rg = 3.126 Å（分子尺寸的特征长度）",
      "非球形度：asphericity = 0.478（显著偏离球形）",
      "偏心率：eccentricity = 0.975（高度拉伸的椭球形）",
      "【合成难度评估】根据SAS=3.5给出合成难度评价",
      "合成难度：相对容易合成（★★☆☆☆）",
      "核苷类似物的典型复杂度，适合药物开发",
      "【药物应用背景】5-FdU是胸苷酸合成酶抑制剂，用于治疗结直肠癌和肝癌",
      "商品名：Floxuridine, FUDR",
      "作用机制：干扰DNA合成，诱导癌细胞凋亡",
      "【最终答案】合成可及性分数 SAS = 3.5"
    ],
    "tool_expected": [
      "calculate_synthetic_accessibility",
      "mol_basic_physicochemical_info",
      "chem_visualizer",
      "optimize_geometry",
      "get_3d_properties"
    ],
    "golden_answer": [
      {
        "(1)": {
          "MW": 246.2,
          "logP": -0.9,
          "TPSA": 92.0,
          "HBD": 3,
          "HBA": 5,
          "RB": 4,
          "Lipinski_violations_eval_1": 0,
          "Lipinski_violations_eval_2": 0,
          "result_relation": "两次结果相同（均满足规则）"
        },
        "(2)": {
          "optimization_method": "ETKDG",
          "force_field": "MMFF",
          "max_iterations": 500,
          "converged": true,
          "total_energy": "72.8 kcal/mol",
          "Rg": 2.35,
          "PMI": [
            120.4,
            230.8,
            350.9
          ],
          "asphericity": 0.24,
          "eccentricity": 0.78
        },
        "(3)": {
          "SAS_raw": 4.7,
          "SAS_final_1dp": 4.7,
          "source": "题面给定SAS_raw",
          "range_check": "[1,10]内"
        },
        "(4)": {
          "path_2D": "/images/Floxuridine_2D.png",
          "path_3D": "/models/Floxuridine_3D.sdf",
          "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
        },
        "(5)": {
          "summary_index": {
            "P1": "(1)中的理化性质与Lipinski评估结果",
            "G1": "(2)中的几何优化与形状描述符",
            "S1": "(3)中的最终SAS",
            "Paths": "(4)中的2D/3D路径"
          },
          "cross_checks": [
            "SAS范围：S1∈[1,10]",
            "Lipinski两次评估结果相同，均满足规则",
            "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
          ],
          "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
        }
      }
    ],
    "original_question_id": "42",
    "test_type": "refined",
    "dataset_key": "merged_questions_augmented",
    "trace_root": "/root/workspace/hbz/MutliSciTool/tracetoanalyze/traces"
  },
  "metadata_summary": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "test_type": "refined",
    "original_question_id": "42",
    "subject_topic_key": "化学::药物化学与合成可及性"
  },
  "answer_template": {
    "(1)": {
      "MW": "[数值]",
      "logP": "[数值]",
      "TPSA": "[数值]",
      "HBD": "[数值]",
      "HBA": "[数值]",
      "RB": "[数值]",
      "Lipinski_violations_eval_1": "[数值]",
      "Lipinski_violations_eval_2": "[数值]",
      "result_relation": "[字符串]"
    },
    "(2)": {
      "optimization_method": "[字符串]",
      "force_field": "[字符串]",
      "max_iterations": "[数值]",
      "converged": "[布尔值]",
      "total_energy": "[字符串]",
      "Rg": "[数值]",
      "PMI": "[3个数值的数组]",
      "asphericity": "[数值]",
      "eccentricity": "[数值]"
    },
    "(3)": {
      "SAS_raw": "[数值]",
      "SAS_final_1dp": "[数值]",
      "source": "[字符串]",
      "range_check": "[字符串]"
    },
    "(4)": {
      "path_2D": "[字符串]",
      "path_3D": "[字符串]",
      "usage": "[字符串]"
    },
    "(5)": {
      "summary_index": {
        "P1": "[字符串]",
        "G1": "[字符串]",
        "S1": "[字符串]",
        "Paths": "[字符串]"
      },
      "cross_checks": "[3个字符串的数组]",
      "overall_conclusion": "[字符串]"
    }
  },
  "golden_standard": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "两次结果相同（均满足规则）"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定SAS_raw",
      "range_check": "[1,10]内"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
    },
    "(5)": {
      "summary_index": {
        "P1": "(1)中的理化性质与Lipinski评估结果",
        "G1": "(2)中的几何优化与形状描述符",
        "S1": "(3)中的最终SAS",
        "Paths": "(4)中的2D/3D路径"
      },
      "cross_checks": [
        "SAS范围：S1∈[1,10]",
        "Lipinski两次评估结果相同，均满足规则",
        "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
      ],
      "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
    }
  },
  "expected_format": "structured_json",
  "model_structured_answer": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "两次评估结果相同"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定",
      "range_check": "通过，值在[1,10]范围内"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "核对嘧啶5位氟取代与糖环手性（相对构型）"
    },
    "(5)": {
      "summary_index": {
        "P1": "理化性质与Lipinski规则",
        "G1": "3D几何与形状描述符",
        "S1": "合成可及性分数",
        "Paths": "2D/3D结构图路径"
      },
      "cross_checks": [
        "SAS范围检查: 通过",
        "理化属性重复评估结果: 相同",
        "形状与理化属性合理性: 合理"
      ],
      "overall_conclusion": "Floxuridine表现出良好的类药性 (Lipinski 0违例)，最终SAS为4.7"
    }
  },
  "answer_extraction_success": true,
  "model_raw_answer": "```json\n{\n  \"(1)\": {\n    \"MW\": 246.20,\n    \"logP\": -0.90,\n    \"TPSA\": 92.00,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"两次评估结果相同\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [\n      120.40,\n      230.80,\n      350.90\n    ],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"题面给定\",\n    \"range_check\": \"通过，值在[1,10]范围内\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化性质与Lipinski规则\",\n      \"G1\": \"3D几何与形状描述符\",\n      \"S1\": \"合成可及性分数\",\n      \"Paths\": \"2D/3D结构图路径\"\n    },\n    \"cross_checks\": [\n      \"SAS范围检查: 通过\",\n      \"理化属性重复评估结果: 相同\",\n      \"形状与理化属性合理性: 合理\"\n    ],\n    \"overall_conclusion\": \"Floxuridine表现出良好的类药性 (Lipinski 0违例)，最终SAS为4.7\"\n  }\n}\n```",
  "model_last_assistant_message": {
    "role": "assistant",
    "content": "```json\n{\n  \"(1)\": {\n    \"MW\": 246.20,\n    \"logP\": -0.90,\n    \"TPSA\": 92.00,\n    \"HBD\": 3,\n    \"HBA\": 5,\n    \"RB\": 4,\n    \"Lipinski_violations_eval_1\": 0,\n    \"Lipinski_violations_eval_2\": 0,\n    \"result_relation\": \"两次评估结果相同\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500,\n    \"converged\": true,\n    \"total_energy\": \"72.8 kcal/mol\",\n    \"Rg\": 2.35,\n    \"PMI\": [\n      120.40,\n      230.80,\n      350.90\n    ],\n    \"asphericity\": 0.24,\n    \"eccentricity\": 0.78\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.7,\n    \"SAS_final_1dp\": 4.7,\n    \"source\": \"题面给定\",\n    \"range_check\": \"通过，值在[1,10]范围内\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化性质与Lipinski规则\",\n      \"G1\": \"3D几何与形状描述符\",\n      \"S1\": \"合成可及性分数\",\n      \"Paths\": \"2D/3D结构图路径\"\n    },\n    \"cross_checks\": [\n      \"SAS范围检查: 通过\",\n      \"理化属性重复评估结果: 相同\",\n      \"形状与理化属性合理性: 合理\"\n    ],\n    \"overall_conclusion\": \"Floxuridine表现出良好的类药性 (Lipinski 0违例)，最终SAS为4.7\"\n  }\n}\n```"
  },
  "evaluation_score": 0.8857142857142857,
  "evaluation_summary": "匹配字段: 31/35 (得分: 88.57%)",
  "evaluation_details": {
    "(1).MW": {
      "path": "(1).MW",
      "expected": 246.2,
      "actual": 246.2,
      "expected_num": 246.2,
      "actual_num": 246.2,
      "status": "match",
      "match_type": "exact"
    },
    "(1).logP": {
      "path": "(1).logP",
      "expected": -0.9,
      "actual": -0.9,
      "expected_num": -0.9,
      "actual_num": -0.9,
      "status": "match",
      "match_type": "exact"
    },
    "(1).TPSA": {
      "path": "(1).TPSA",
      "expected": 92.0,
      "actual": 92.0,
      "expected_num": 92.0,
      "actual_num": 92.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBD": {
      "path": "(1).HBD",
      "expected": 3,
      "actual": 3,
      "expected_num": 3.0,
      "actual_num": 3.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBA": {
      "path": "(1).HBA",
      "expected": 5,
      "actual": 5,
      "expected_num": 5.0,
      "actual_num": 5.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).RB": {
      "path": "(1).RB",
      "expected": 4,
      "actual": 4,
      "expected_num": 4.0,
      "actual_num": 4.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_1": {
      "path": "(1).Lipinski_violations_eval_1",
      "expected": 0,
      "actual": 0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_2": {
      "path": "(1).Lipinski_violations_eval_2",
      "expected": 0,
      "actual": 0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).result_relation": {
      "path": "(1).result_relation",
      "expected": "两次结果相同（均满足规则）",
      "actual": "两次评估结果相同",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(2).optimization_method": {
      "path": "(2).optimization_method",
      "expected": "ETKDG",
      "actual": "ETKDG",
      "status": "match",
      "match_type": "exact"
    },
    "(2).force_field": {
      "path": "(2).force_field",
      "expected": "MMFF",
      "actual": "MMFF",
      "status": "match",
      "match_type": "exact"
    },
    "(2).max_iterations": {
      "path": "(2).max_iterations",
      "expected": 500,
      "actual": 500,
      "expected_num": 500.0,
      "actual_num": 500.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).converged": {
      "path": "(2).converged",
      "expected": true,
      "actual": true,
      "expected_num": 1.0,
      "actual_num": 1.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).total_energy": {
      "path": "(2).total_energy",
      "expected": "72.8 kcal/mol",
      "actual": "72.8 kcal/mol",
      "status": "match",
      "match_type": "exact"
    },
    "(2).Rg": {
      "path": "(2).Rg",
      "expected": 2.35,
      "actual": 2.35,
      "expected_num": 2.35,
      "actual_num": 2.35,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[0]": {
      "path": "(2).PMI[0]",
      "expected": 120.4,
      "actual": 120.4,
      "expected_num": 120.4,
      "actual_num": 120.4,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[1]": {
      "path": "(2).PMI[1]",
      "expected": 230.8,
      "actual": 230.8,
      "expected_num": 230.8,
      "actual_num": 230.8,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[2]": {
      "path": "(2).PMI[2]",
      "expected": 350.9,
      "actual": 350.9,
      "expected_num": 350.9,
      "actual_num": 350.9,
      "status": "match",
      "match_type": "exact"
    },
    "(2).asphericity": {
      "path": "(2).asphericity",
      "expected": 0.24,
      "actual": 0.24,
      "expected_num": 0.24,
      "actual_num": 0.24,
      "status": "match",
      "match_type": "exact"
    },
    "(2).eccentricity": {
      "path": "(2).eccentricity",
      "expected": 0.78,
      "actual": 0.78,
      "expected_num": 0.78,
      "actual_num": 0.78,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_raw": {
      "path": "(3).SAS_raw",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_final_1dp": {
      "path": "(3).SAS_final_1dp",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).source": {
      "path": "(3).source",
      "expected": "题面给定SAS_raw",
      "actual": "题面给定",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(3).range_check": {
      "path": "(3).range_check",
      "expected": "[1,10]内",
      "actual": "通过，值在[1,10]范围内",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(4).path_2D": {
      "path": "(4).path_2D",
      "expected": "/images/Floxuridine_2D.png",
      "actual": "/images/Floxuridine_2D.png",
      "status": "match",
      "match_type": "exact"
    },
    "(4).path_3D": {
      "path": "(4).path_3D",
      "expected": "/models/Floxuridine_3D.sdf",
      "actual": "/models/Floxuridine_3D.sdf",
      "status": "match",
      "match_type": "exact"
    },
    "(4).usage": {
      "path": "(4).usage",
      "expected": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性",
      "actual": "核对嘧啶5位氟取代与糖环手性（相对构型）",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.P1": {
      "path": "(5).summary_index.P1",
      "expected": "(1)中的理化性质与Lipinski评估结果",
      "actual": "理化性质与Lipinski规则",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.G1": {
      "path": "(5).summary_index.G1",
      "expected": "(2)中的几何优化与形状描述符",
      "actual": "3D几何与形状描述符",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.S1": {
      "path": "(5).summary_index.S1",
      "expected": "(3)中的最终SAS",
      "actual": "合成可及性分数",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.Paths": {
      "path": "(5).summary_index.Paths",
      "expected": "(4)中的2D/3D路径",
      "actual": "2D/3D结构图路径",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[0]": {
      "path": "(5).cross_checks[0]",
      "expected": "SAS范围：S1∈[1,10]",
      "actual": "SAS范围检查: 通过",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).cross_checks[1]": {
      "path": "(5).cross_checks[1]",
      "expected": "Lipinski两次评估结果相同，均满足规则",
      "actual": "理化属性重复评估结果: 相同",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[2]": {
      "path": "(5).cross_checks[2]",
      "expected": "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征",
      "actual": "形状与理化属性合理性: 合理",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(5).overall_conclusion": {
      "path": "(5).overall_conclusion",
      "expected": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征",
      "actual": "Floxuridine表现出良好的类药性 (Lipinski 0违例)，最终SAS为4.7",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    }
  },
  "mode_folder": "with_tools_react"
}